Meinolf Karthaus1,2, Gülten Oskay-Özcelik3, Pia Wülfing4, Carsten Hielscher5, Dagmar Guth6, Mark-Oliver Zahn7, Elisa Flahaut8, Jörg Schilling3. 1. Department of Hematology, Oncology & Palliative Care, Klinikum Neuperlach, Munich, Germany. 2. Department of Hematology, Oncology & Palliative Care, Klinikum Harlaching, Munich, Germany. 3. Gynecological Oncology Practice, Berlin, Germany. 4. Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg, Germany. 5. Gynecological Oncology Center, Stralsund, Germany. 6. Gynecological Oncology Practice, Plauen, Germany. 7. Oncology Center Harz, Goslar, Germany. 8. Department of Medical Affairs, RIEMSER Pharma GmbH, Berlin, Germany.
Abstract
Aim: To determine quality of life, effectiveness and safety of oral netupitant-palonosetron (NEPA)-based antiemetic prophylaxis in the real-world setting. Materials & methods: Prospective, noninterventional study in adults receiving highly or moderately emetogenic chemotherapy and NEPA for three cycles. NEPA was administered per summary of product characteristics. Results: A total of 2429 patients enrolled, 2173 were evaluable. 'No impact on daily life' due to vomiting was reported by 85%/82% of patients in the highly emetogenic chemotherapy/moderately emetogenic chemotherapy groups in cycle 1, with rates of 54%/59% for nausea. Overall, complete response rate was 89%/87%/83% in the acute/delayed/overall phases. NEPA was well tolerated. Conclusion: NEPA had beneficial effects on the quality of life of a heterogeneous group of cancer patients and was safe and effective in the real-world setting.
Aim: To determine quality of life, effectiveness and safety of oral netupitant-palonosetron (NEPA)-based antiemetic prophylaxis in the real-world setting. Materials & methods: Prospective, noninterventional study in adults receiving highly or moderately emetogenic chemotherapy and NEPA for three cycles. NEPA was administered per summary of product characteristics. Results: A total of 2429 patients enrolled, 2173 were evaluable. 'No impact on daily life' due to vomiting was reported by 85%/82% of patients in the highly emetogenic chemotherapy/moderately emetogenic chemotherapy groups in cycle 1, with rates of 54%/59% for nausea. Overall, complete response rate was 89%/87%/83% in the acute/delayed/overall phases. NEPA was well tolerated. Conclusion:NEPA had beneficial effects on the quality of life of a heterogeneous group of cancerpatients and was safe and effective in the real-world setting.
Entities:
Keywords:
CINV; FLIE; NEPA; effectiveness; highly emetogenic chemotherapy; moderately emetogenic chemotherapy; quality of life; real world
Authors: Matti Aapro; Florian Scotté; Yolanda Escobar; Luigi Celio; Richard Berman; Alessandra Franceschetti; Danielle Bell; Karin Jordan Journal: Oncologist Date: 2021-03-17
Authors: Winnie Yeo; Frankie K F Mo; Christopher C H Yip; Victoria A Yeo; Leung Li; Thomas K H Lau; Kwai T Lai; Vicky T C Chan; Kwan H Wong; Elizabeth Pang; Maggie Cheung; Vivian Chan; Carol C H Kwok; Joyce J S Suen; Alex Molassiotis Journal: Oncologist Date: 2021-09-25